Clinical trials: Hemolysis
Sickle Cell Anemia
The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia
The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.
- Trial name
- NCT01703104
- Testing
- Paludrine + Folic Acid, Paludrine + Folic Acid + Jobelyn
- Where
- Nigeria
- Volunteers
- 150 people
- Sponsor
- Lagos State University
Sickle Cell Disease
Improving Self-Management in Adolescents With Sickle Cell Disease
The objective of this study is to determine the feasibility and acceptability of SCThrive, a an innovative, technology-enhanced, group self-management intervention that uses a mixed in-person and online format and supported by a…
- Trial name
- SCThrive (NCT02851615)
- Testing
- SCThrive Intervention for Adolescents with SCD
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sickle Cell Disease
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
This study consists of four parts, Parts A, B, C, and D. Part A is a single dose pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease ages 6 to 17 years.
- Trial name
- HOPE-KIDS (NCT02850406)
- Testing
- Voxelotor
- Where
- 20 sites in United States, Lebanon and 1 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Sickle Cell Anemia, Pulmonary Hypertension
Heart Disease in Sickle Cell Anemia
This study will explore what may cause people with sickle cell anemia to have heart problems and an increased risk of sudden death. People 18 years of age and older with sickle cell anemia may be eligible for this study.
- Trial name
- NCT00113152
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
Group A Streptococcus (GAS) infection is a major cause of death and disability globally with a disproportionately high burden in settings of disadvantage worldwide.
- Conditions
- Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis, Strep Throat, Streptococcus Pyogenes Infection
- Trial name
- CHIVAS (NCT03361163)
- Testing
- emm75 Streptococcus pyogenes (GAS M75, strain 611024)
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Andrew Steer
Haemolysis Neonatal
Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born
- Trial name
- IVIG (NCT03130517)
- Testing
- intravenous immunoglobulin
- Volunteers
- 30 people
- Sponsor
- Assiut University
Sickle Cell Disease, Sickle Cell Anemia
Hydroxyurea Optimization Through Precision Study
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for…
- Trial name
- HOPS (NCT03789591)
- Testing
- Hydroxyurea
- Where
- 13 sites in United States
- Volunteers
- 104 people
- Sponsor
- Lifespan
Sickle Cell Disease, Cognitive Impairment
Cognitive Rehabilitation in Sickle Cell Disease
The majority of school-age children with sickle cell disease (SCD) experience neurocognitive deficits, even in the absence of stroke.
- Trial name
- NCT01793740
- Testing
- Cogmed
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Beta-thalassemia, Iron Overload
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
- Trial name
- NCT00447694
- Testing
- Deferasirox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
Sickle Cell Disease
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can…
- Trial name
- SUN (NCT03587272)
- Testing
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Where
- 7 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Robert Nickel
Warm Autoimmune Hemolytic Anemia
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment.
- Trial name
- NCT05922839
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Chen Miao
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).
- Trial name
- NCT07603557
- Testing
- BMS-986353, Fludarabine Phosphate, Cyclophosphamide
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Transfusional Iron Overload, Beta-thalassemia
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver.
- Trial name
- NCT01186419
- Testing
- SPD602 (FBS0701, SSP-004184)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 51 people
- Sponsor
- Shire
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Splenectomy
Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations
Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response…
- Trial name
- SPLEENVIVO (NCT06418256)
- Testing
- Spleen, blood and plasma collection
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thalassemia, Hepatitis C
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
Sustained Viral Response following 12-week therapy (SVR 12) with sofosbuvir/ledipasvir in transfusion-dependent patients with HCV genotype 1-6 Secondary Objective(s): Assessment of transfusion requirements Adverse events Efficacy…
- Trial name
- NCT03032666
- Testing
- sofosbuvir/velpatasvir
- Where
- Lebanon
- Volunteers
- 7 people
- Sponsor
- Ala'a Sharara
Anemia, Sickle Cell
A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO)…
- Trial name
- NCT03926819
- Testing
- HBI-002
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
Sickle Cell Disease
Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)
The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on…
- Trial name
- NCT01411280
- Testing
- methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Temple University
Paroxysmal Nocturnal Hemoglobinuria
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT06028594
- Testing
- Pozelimab, Cemdisiran
- Sponsor
- Regeneron Pharmaceuticals
Sickle Cell Disease
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
- Trial name
- NCT05632354
- Testing
- Osivelotor
- Where
- 9 sites in United States, Nigeria
- Volunteers
- 47 people
- Sponsor
- Pfizer